Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

iSoftStone Subsidiary Signs USD 190 Million MECHREVO Laptop Contract

iSoftStone（软通动力）said on October 27 that its wholly owned subsidiary Aistone Global Limited（智通国际）had signed a USD 190.35 million contract to supply 309,000 MECHREVO（机械革命）laptops and warranty services through local repair centres.

Lens Technology Reports AI Server Component Orders as Dongguan Capacity Enters Ramp-Up

Lens Technology（蓝思科技）said in an October 26 investor-relations disclosure that it had completed an expansion of AI server-related capacity at its Songshan Lake campus in Dongguan. The company said liquid-cooling modules, high-end precision cabinets and high-speed optical interconnect components had passed validation by leading North American computing companies and secured volume orders, with production entering the ramp-up stage.

DSBJ Sets Hong Kong Offer Price at HK$86.80 Ahead of Planned October 28 Listing

Suzhou Dongshan Precision Manufacturing Co., Ltd.（苏州东山精密制造股份有限公司）, known as DSBJ, disclosed a final Hong Kong offer price of HK$86.80 per share ahead of its scheduled October 28 main-board debut. The offering would give the Chinese electronics manufacturer an additional offshore financing channel as it expands its printed circuit board and optical communications businesses.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.